|
⚲
|
| Keyboard |
| Symbiotic Capital Management Co LLC
✚
|
|
|---|---|
| CRD # | 325844 |
| SEC # | 801-128442 |
| CIK # | |
| AUM | 1,134.5 M (2026-03-31) |
| Employees | 9 (67% Investors, 0% Brokers) |
| Phone | 424-313-1550 |
| Address | 10100 Santa Monica Blvd Los Angeles, CA 90067 |
| Source | [IAPD] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | SC Healthcare Credit Parallel Fund II A LP | [2026-03-31] | 100.0 M | 117.5 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | SC Opportunities Holding LP | 2026-03-31 | 34.7 M | |
| Other | Symbiotic Capital Healthcare Credit Fund II LP | [2026-03-31] | 67.5 M | 115.7 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital Healthcare Credit Parallel Fund II LP | [2026-03-31] | 137.9 M | 155.0 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | SC Life Science Credit Parallel Fund A LP | [2025-03-31] | 242.4 M | 247.4 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | Symbiotic Capital EB Fund LP | [2025-03-31] | 15.1 M | |
| Filed 2025-03-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital EB Parallel Fund LP | [2025-03-31] | 8.8 M | |
| Filed 2025-03-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital Life Science Credit Fund LP | [2023-06-01] | 160.2 M | 172.5 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $1,200,000 · Net Assets Decline to Disclose | ||||
| Other | Symbiotic Capital Life Science Credit Parallel Fund LP | [2023-06-01] | 176.4 M | 267.7 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $1,200,000 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 1,134.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 1,134.5 |
| By Discretionary | ||
| Discretionary | 8 | 1,099.8 |
| Non-Discretionary | 1 | 34.7 |
| Total | 9 | 1,134.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 370.8 | |
| United States Persons | 763.7 | |
| Total | 9 | 1,134.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Arie Belldegrun | Director | 50 | 6 | |
| Joshua Kazam | Director | 60 | 3 | |
| Daniel Kim | Director | 47 | 3 | |
| Joshua Bradley | Director | 32 | 3 | |
| Benjamin Belldegrun | Director | 7 | 3 | |
| Franz Humer | Director | 6 | 2 | |
| Russell Goldsmith | Director | 8 | 1 | |
| Himani Bhalla | Director | 8 | 1 | |
| Symbiotic Capital Life Science Credit Fund GP LP | Promoter | 5 | 1 | |
| Symbiotic Capital Healthcare Credit Fund II GP LP | Promoter | 3 | 1 |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Comparable Firms | State | AUM |
|---|---|---|
|
Astatine Asset Management LLC
✚
|
CT | 1,150.1 M |
|
Viking Fund Management LLC
✚
|
ND | 1,149.5 M |
|
1WS Capital Advisors LLC
✚
|
NY | 1,142.6 M |
|
Yosemite Management LLC
✚
|
CA | 1,135.7 M |
|
HM International LLC
✚
|
TX | 1,134.4 M |
|
iCapital Fund Advisors LLC
✚
|
NY | 1,132.6 M |
|
Amundi US Investment Advisors LLC
✚
|
MA | 1,132.5 M |
|
Moonrise Capital LP
✚
|
FL | 1,128.2 M |
|
WITT Lake Asset Management LLC
✚
|
CT | 1,120.4 M |
|
New Century Partners
✚
|
1,118.9 M |